180 Life Sciences Corp. (ATNF)
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
$1.89M
Dr. James N. Woody M.D., Ph.D.
Palo Alto, CA
Jun 07, 2018
-0.17
$-11.20
0.29
0.58
-7,559.37%
-0.14
-0.00
-4.29
11.39
0.58
-320.87%
3,043.52%
Similar stocks (10)
Immix Biopharma, Inc.
IMMX
Cardio Diagnostics Holdings, Inc.
CDIO
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Enveric Biosciences, Inc.
ENVB
Palisade Bio, Inc.
PALI
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (10)
Immix Biopharma, Inc.
IMMX
Cardio Diagnostics Holdings, Inc.
CDIO
CNS Pharmaceuticals, Inc.
CNSP
Sonnet BioTherapeutics Holdings, Inc.
SONN
Enveric Biosciences, Inc.
ENVB
Palisade Bio, Inc.
PALI
ZyVersa Therapeutics, Inc.
ZVSA
Phio Pharmaceuticals Corp.
PHIO
eFFECTOR Therapeutics, Inc.
EFTR
Navidea Biopharmaceuticals, Inc.
NAVB
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%